Akoya Biosciences Inc

85 articles about Akoya Biosciences Inc

• Akoya Set to Join Russell 3000® Index

  6/9/2021

  Akoya Biosciences, Inc., The Spatial Biology Company®, is set to join the broad-market Russell 3000® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28, 2021, according to a preliminary list of additions posted by FTSE Russell on June 4, 2021.

• Akoya and AstraZeneca to Collaborate on Spatial Biology Approach to Profiling Tumor-Immune Biology

  6/4/2021

  Partnership aims to leverage spatial biology data, generated on Akoya’s Phenoptics™ platform, to inform and guide drug development programs

• Akoya Announces Rollout of Strategic Clinical Research Program to Advance Adoption of Spatial Biology for Clinical Applications

  6/2/2021

  Company launches Advanced Biopharma Solutions (ABS), as the first pillar of the program, to enable spatial biomarker-guided drug development and clinical trials

• Akoya Reports First Quarter 2021 Financial Results and Issues Full Year 2021 Guidance

  5/18/2021

  Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2021. First Quarter Financial Highlights: Total revenue for the first quarter of 2021 was $12.2 million, at the high end of the previously provided range of $12.0 million to $12.2 million.

• Akoya to Report First Quarter 2021 Financial Results on May 18, 2021

  5/12/2021

  Akoya Biosciences, Inc., The Spatial Biology Company®, announced that it will release financial results for the first quarter of 2021 after the market close on Tuesday, May 18, 2021.

• Akoya Biosciences Begins Accepting Applications for First-of-its-Kind Imaging Innovators (I²) Network

  5/11/2021

  Seeking researchers interested in pushing the boundaries of spatial biology and discovery through the CODEX® system’s open, accessible interface

• Akoya Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

  4/20/2021

  Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced the closing of its initial public offering of 7,567,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase 987,000 additional shares of common stock, at the initial public offering price of $20.00 per share.

• Akoya Biosciences Announces Pricing of Initial Public Offering - Apr 16, 2021

  4/16/2021

  Akoya Biosciences, Inc., The Spatial Biology Company®, announced the pricing of its initial public offering of 6,580,000 shares of its common stock at a price of $20.00 per share, for gross proceeds of $131.6 million, before underwriting discounts and commissions and offering expenses payable by Akoya.

• Akoya Appoints Industry Leader Frederic Pla as Chief Operating Officer to Spearhead Growth Initiatives

  4/5/2021

  Akoya Biosciences, Inc., The Spatial Biology Company ® , today announced the appointment of Frederic Pla, PhD, as Chief Operating Officer. Dr. Pla will play a key role in preparing the company as it scales to serve the needs of discovery and clinical researchers adopting spatial biology. This press release features multimedia. View the

• Akoya to Help Support the Human Cell Atlas (HCA) Initiative with Single-Cell, Spatial Imaging Capabilities

  3/23/2021

  Akoya Biosciences, Inc., The Spatial Biology Company ® , today announced its support for the Human Cell Atlas (HCA) initiative, offering the CODEX ® solution’s single-cell, whole-tissue imaging capabilities to HCA members under favorable commercial terms.

• Akoya and Johns Hopkins’ Collaborative Agreement Supports Pioneering New Approach to Immunotherapy Biomarker Discovery and Validation

  3/2/2021

  Akoya Biosciences, Inc., The Spatial Biology Company®, today announced a collaboration with the Bloomberg-Kimmel Institute for Cancer Immunotherapy (BKI) and the Bloomberg Center for Physics and Astronomy at the Johns Hopkins University School of Medicine

• Akoya Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021

  1/11/2021

  Akoya Biosciences to Present at the 39 th Annual J.P. Morgan Healthcare Conference on January 13, 2021

• Akoya’s CODEX® System Utilized in Novel Study of Muscle Strength and Aging Published in Science

  12/11/2020

  Akoya Biosciences, Inc., The Spatial Biology Company®, today announced that CODEX was used for spatial phenotyping to identify the source of a protein that can reverse age-related muscle atrophy.

• Akoya Biosciences Receives ISO 13485:2016 Quality Certification

  10/13/2020

  Akoya Biosciences, Inc., The Spatial Biology Company®, today announced that the company received ISO 13485:2016 certification for the design, development, production, distribution and installation of medical devices and related services. Achieving this ISO certification s

• Akoya Biosciences Unveils New Spatial Biology Platform to Enable Rapid Image Analysis and Secure Data Sharing

  9/15/2020

  Akoya Biosciences, Inc., The Spatial Biology Company™, today announced the availability of Proxima™, The Spatial Biology Platform™ to integrate rapid image acquisition and secure data sharing in the cloud with immediate access from anywhere for geographically distributed and remote teams, including those working from home during the COVID-19 pandemic.

• 

  BioSpace Movers & Shakers, Sept. 4

  9/4/2020

  Biopharma and life science companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers.

• Akoya Biosciences Strengthens Leadership Team with Spatial Biology and Molecular Pathology Experts

  9/2/2020

  Akoya Biosciences, Inc., The Spatial Biology Company™, today announced the expansion of its leadership team with the appointment of two senior leaders with expertise in spatial biology and molecular pathology.

• Landmark Cell Publication Reveals Novel Spatial Biology Discoveries Enabled by the CODEX® Platform

  8/12/2020

  Landmark Cell Publication Reveals Novel Spatial Biology Discoveries Enabled by the CODEX® Platform New peer-reviewed paper outlines novel organizing principles and spatial interactions between “neighborhoods” of cells in the tumor microenvironment of colorectal cancer. MENLO PARK, Calif.--( BUSINESS WIRE )-- Akoya Biosciences, Inc., The Spatial Biology Company™, today announced the application of the CODEX® platform to a recent Cell publication ti

• Akoya Biosciences Collaborates with Leading Cancer Center to Discover Predictive Biomarkers for Cancer

  7/29/2020

  University of California San Francisco (UCSF) uses Phenoptics™ platform to help with biomarker discovery Akoya, UCSF and the I-SPY TRIAL consortium collaborate to discover and validate biomarker signatures for predicting response to neoadjuvant and adjuvant immunotherapies MENLO PARK, Calif.--( BUSINESS WIRE )-- Akoya Biosciences, Inc., The Spatial Biology Company™, today announced a collaboration with UCSF Helen Diller Family Comprehe

• Akoya Biosciences Raises $50 Million in New Financing

  12/5/2019

  Akoya Biosciences, Inc., The Spatial Biology Company™, today announced the completion of a $50 million financing from both new and existing investors.